Outcome of Board Meeting

BDL/PKL/SEC/2026-27 20th July, 2026 The Listing Department National Stock Exchange of India Ltd. Exchange Plaza, 5th Floor Plot no. C/l, G Block Bandra-Kurla Complex, Bandra (E) Mumbai — 400 051. Subject: Outcome of the Board Meeting held on Monday, 20thJuly, 2026 – Q1 Results Dear Sir/Madam, With reference to above captioned subject matter we would like to inform you that Board of Directors of Beta Drugs Limited in their meeting held today i.e. 20th July, 2026, at 8:00 AM at the Corporate Office of the company situated at SCO-184, Sector-5, Panchkula-134114 has considered and approved the following agenda items:- 1. The un-audited Standalone & Consolidated financial results alongwith limited review report under regulation 33 of SEBI (LODR) Regulation, 2015 for the quarter ended 30th June, 2026. Pursuant to Regulation 33 of SEBI (Listing Obligation & Disclosure Requirements) Regulation, 2015, we are enclosing herewith the following documents: 1. Management Discussion & Analysis. 2. Limited review Report on Consolidated Financial Results alongwith Un-Audited Consolidated Financial Results for the quarter ended 30th June, 2026. 3. Limited review Report on Standalone Financial Results alongwith Un-Audited Standalone Financial Results for the quarter ended 30th June, 2026. 4. Certificate as per regulation 33(2)(a) of SEBI (LODR) Regulations, 2015 The meeting of the Board of Directors commenced at 8.00 a.m. and concluded at 8:50 a.m. This is for your information and appropriate dissemination Thanking You Your’s faithfully For Beta Drugs Ltd. Rajni Brar Company Secretary BETA DRUGS LIMITED Q1FY27 Results Announcement Beta Reports Q1FY27 Results — Strong performance across business segments drives superior performance Beta recorded consolidated total sales of Rs 125.55 crores for Q1FY27, a 25.3% increase from Rs 100.2 crores in the previous fiscal year. The total revenues were Rs. 127.13 crores. Segmental Performance Branded oncology: The business continued to deliver stellar performance delivering growth of 47% y-o-y recording sales of INR 33.0 Crores. The growth was on the back of improved performance from existing products and increasing acceptance of our new launches last year. CMO: Our CMO business delivered robust performance for the quarter and grew by 41% y-o-y on the back of strong traction with our customers and new launches including our proprietary NDDS products in CMO segment. With higher realisations in platins going forward, we expect this business to deliver better performance in FY27. Exports: Our exports business delivered INR 17.2 Crores in Q1FY27. The business is expected to record a higher growth for the remainder of FY27 as the orders have started to accelerate. Nivian: Nivian delivered a growth of 45% y-o-y. The higher growth stems from increased penetration and full quarter performance of new products launched in the last quarter of FY26. Consolidated EBITDA stood at Rs. 28.95 crores (including other income) and Rs 27.37 Crores (excluding other income), with EBITDA margins at 23.06% (including other income) and 21.80% in Q1FY27 (excluding other income). Consolidated EBITDA (excluding other income) grew by 38.9% y-o-y. Net of Nivian, Beta delivered EBITDA of INR 24.5 Crores (excluding other income) demonstrating a growth of 24.5% y-o-y. Improved margins are driven by higher Gross Margins (56.6% in Q1FY27 v/s 50.4% in Q1FY26) on account of change in sales mix towards branded businesses including Nivian. This improvement in EBITDA margins is expected to continue as the business mix moves favourably towards higher contributions from branded and exports. Beta recorded Net profit of INR 16.5 Crs. (net margin: 13.1%) compared to INR 11.7 Crs. in Q1FY26 which shows 40.92% growth. The improvement in Net Profit was on account of reduced finance costs associated with conversion CCDs issued in Nov 2024 and converted in May 2026. The interest cost associated with CCDs was INR 0.75 Crores for Q1FY27 compared to INR 2.1 Crores in Q1FY26. CIN No.: L24230HP2005PLC028969 Admin. Office: SCO 184, Sector-5, Panchkula-134 114 Haryana (INDIA) | Phone: +91-172-2585481-482-483 Registered Office & Works: Vill. Nandpur, Lodhimajra Road, Tehsil. Baddi, Distt. Solan, H.P. | Phone No.: 01795-236196 Website: www.betadrugslimited.com | E-Mail: info@betadrugslimited.com Page 1 of 2 Beta had set out a vision for 2030 which sets a target for accelerated growth and higher margins. We continue to reiterate our expectations in delivering higher growth across our businesses. Our high margin businesses including own branded products and exports are expected to contribute >80% of the total turnover by 2030. Beta continues to be one of the fastest-growing players in the Indian branded oncology pharmaceutical market, gaining market share y-o-y and is also emerging a strong innovation focused player. The focus on R&D has led to the launch of differentiated products (NDDS, “first to launch” in India etc.) and strengthened its presence both in India and international markets. Outlook We continue to work towards our vision 2030 - a leading formulations company with more than 50% of the turnover coming from own branded products. We are on track to deliver a 20-25% growth on a consolidated basis for FY27. Our backward integration in KSMs and advanced intermediates is expected to result in strong improvement in our operating margins coupled with change in product mix towards branded business. Nivan will continue to deliver exceptional growth in a fast-growing market through deeper penetration and new product launches. Synergies with Beta are expected to result in higher operating margins for Nivian in FY27 and thereafter. We continue to invest in R&D and have a robust pipeline of NDDS products for launch in FY27 and FY28. This is in addition to new launches where Beta will strive to be either First to Launch / First few to Launch in India. As the oncology market continues to expand globally, Beta is at the forefront to meet the growing demand for effective cancer treatments in both domestic and international markets. CIN No.: L24230HP2005PLC028969 Admin. Office: SCO 184, Sector-5, Panchkula-134 114 Haryana (INDIA) | Phone: +91-172-2585481-482-483 Registered Office & Works: Vill. Nandpur, Lodhimajra Road, Tehsil. Baddi, Distt. Solan, H.P. | Phone No.: 01795-236196 Website: www.betadrugslimited.com | E-Mail: info@betadrugslimited.com Page 2 of 2 KHURANA SHARMA & COMPANY CHARTERED ACCOUNTANTS H.No. 1299, SECTOR l5-8, CHANDIGARH PHONE : 9988070254, 9878029920 LIMITED REVIEW REPORT INDEPENDENTAUDITOR'S REVIEW REPORT ON C The Board of Directors Beta Drugs Limited Village Nandpur, Lodhimajra Road Baddi, Distt. Solan H.P. 1741.01 1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of BETA DRUGS LIMITED ("the Parent") and its subsidiary ("the Parent" and its subsidiaries together referred to as "the Group"), and its share of the net profit/(loss) after tax for the quarter ended 3Oth June,2026 being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. 2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "lnterim Financial Reporting" ("lnd AS 34"), prescribed under Section 133 of the Companies Act, 201-3 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on these financial statements based on our review. 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410'Review of Interim Financial lnformation Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India [Showing first 8,000 characters — download PDF for full document]